2021
Combined liver–cytokine humanization comes to the rescue of circulating human red blood cells
Song Y, Shan L, Gbyli R, Liu W, Strowig T, Patel A, Fu X, Wang X, Xu ML, Gao Y, Qin A, Bruscia EM, Tebaldi T, Biancon G, Mamillapalli P, Urbonas D, Eynon E, Gonzalez DG, Chen J, Krause DS, Alderman J, Halene S, Flavell RA. Combined liver–cytokine humanization comes to the rescue of circulating human red blood cells. Science 2021, 371: 1019-1025. PMID: 33674488, PMCID: PMC8292008, DOI: 10.1126/science.abe2485.Peer-Reviewed Original ResearchConceptsRed blood cellsBlood cellsHuman sickle cell diseaseSickle cell diseaseImmunodeficient murine modelKupffer cell densityBone marrow failureMISTRG miceIntrasplenic injectionSCD pathologyCell diseaseMurine modelComplement C3RBC survivalVivo modelHuman cytokinesPreclinical testingHematopoietic stem cellsHuman red blood cellsMarrow failureFumarylacetoacetate hydrolase geneHuman erythropoiesisHuman liverHuman hepatocytesMice
2018
Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA A Pilot Study
Biancon G, Gimondi S, Vendramin A, Carniti C, Corradini P. Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA A Pilot Study. Journal Of Molecular Diagnostics 2018, 20: 859-870. PMID: 30165206, DOI: 10.1016/j.jmoldx.2018.07.006.Peer-Reviewed Original ResearchConceptsTumor plasma cellsMultiple myelomaPlasma cellsResidual diseasePlasma samplesPilot studySecond-line therapyCell-free tumor DNA analysisMultiple myeloma patientsConventional laboratory parametersSerial plasma samplesMinimal residual diseaseBone marrow aspirateNumber of PCsTumor DNA analysisA Pilot StudyClonal IgH rearrangementsClonal IgH gene rearrangementsIgH gene rearrangementTumor clonotypesComplete responseLaboratory parametersMyeloma patientsCfDNA levelsTumor levelsAnalysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups
Bolli N, Biancon G, Moarii M, Gimondi S, Li Y, de Philippis C, Maura F, Sathiaseelan V, Tai YT, Mudie L, O’Meara S, Raine K, Teague JW, Butler AP, Carniti C, Gerstung M, Bagratuni T, Kastritis E, Dimopoulos M, Corradini P, Anderson KC, Moreau P, Minvielle S, Campbell PJ, Papaemmanuil E, Avet-Loiseau H, Munshi NC. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia 2018, 32: 2604-2616. PMID: 29789651, PMCID: PMC6092251, DOI: 10.1038/s41375-018-0037-9.Peer-Reviewed Original Research
2016
Circulating miRNA panel for prediction of acute graft-versus-host disease in lymphoma patients undergoing matched unrelated hematopoietic stem cell transplantation
Gimondi S, Dugo M, Vendramin A, Bermema A, Biancon G, Cavané A, Corradini P, Carniti C. Circulating miRNA panel for prediction of acute graft-versus-host disease in lymphoma patients undergoing matched unrelated hematopoietic stem cell transplantation. Experimental Hematology 2016, 44: 624-634.e1. PMID: 27013207, DOI: 10.1016/j.exphem.2016.03.005.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBiomarkersCluster AnalysisCombined Modality TherapyFemaleGene ExpressionGene Expression ProfilingGene Regulatory NetworksGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansLymphomaMaleMicroRNAsMiddle AgedPrognosisReproducibility of ResultsTime FactorsTransplantation, HomologousYoung AdultConceptsAllo-HSCTLymphoma patientsReal-time polymerase chain reactionAcute graftPolymerase chain reactionAllogeneic hematopoietic stem cell transplantationUnrelated hematopoietic stem cellHematopoietic stem cell transplantationHost disease (GVHD) resultsNon-aGVHD patientsStem cell transplantationChain reactionQuantitative real-time polymerase chain reactionRoutine clinical useCutaneous GVHDIntestinal GVHDHost diseaseSignificant morbidityUnrelated donorsCell transplantationPredictive biomarkersMicroRNA expression profileBlood samplingTherapeutic strategiesPatients